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Genes located in  the major histocompatibility complex (MHC) 1 influence T-cell- 
mediated cytotoxicity against virally infected or hapten-modified target ceils at several 
different levels. First, MHC products act as recognition structures and eventually as 
restriction  elements  at  the  target  cell  surface.  Second,  genes  in  the  MHC  govern, 
through  various  mechanisms,  the  development  of cytotoxic  T  lymphocyte  (CTL) 
responses. In man, CTL raised against influenza virus-induced antigens are subject to 
allogeneic restriction  (1).  Similar data  have been reported  for human  CTL against 
minor histocompatibility antigens (2) and haptens (3). On the other hand, no evidence 
for allogeneic restriction  has been  found  in  other systems, such  as T-cell-mediated 
cytotoxicity against trinitrophenyl (TNP)-modified human targets (4) or in the mouse 
against  Sendai"  virus-infected  cells  (5).  However,  in  these  nonrestricted  responses, 
quantitative  differences in  the  levels of cytotoxicity with  different  individuals  and 
different  effector-target  cell  combinations  were  obtained  (4).  Several  MHC-linked 
factors may contribute to this apparent polymorphism. Not only may cross-reactivity 
occasionally occur, masking the role of the MHC products as restriction elements (6), 
but  the  level of CTL responses  may be controlled  by MHC-located  genes  such  as 
immune response (Ir)  (7) or viral susceptibility genes (8). 
In human  infectious mononucleosis  (IM), peripheral  T  lymphocytes taken at the 
acute  phase of the  disease,  are specifically cytotoxic  for Epstein-Barr  virus  (EBV)- 
positive  cell  lines  (9).  We  have  previously  shown  in  this  system  that  Daudi  cells 
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and Institut Gustave-Roussy  (grant 76 A 22). 
l Abbreviations used in this paper: ADCC, antibody-dependent cell-mediated cytotoxicity; CTL, cytotoxic 
T lymphocyte(s); DMSO, dimethylsulfoxide; EBV, Epstein°Barr virus; IM, infectious mononucleosis; It, 
immune response; MHC, major histocompatibility  complex; NK cell, natural killer cell; PBL, peripheral 
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lacking HLA-A, B, and C  antigens, although EBV-positive, were resistant to lysis by 
anti-EBV  CTL  (10).  On  the  other  hand,  preliminary evidence  has  been  reported, 
arguing against the existence of allogeneic restriction in this system (9-1 I). 
In the present work, we analyze this system further and, first, confirm that HLA is 
indeed involved in the structure(s)  recognized by anti-EBV  CTL  because, not  only 
are Daudi cells not  killed, but  also anti-fl2 microglobulin and  anti-HLA antibodies 
inhibit  the cytolysis of EBV-positive, HLA-positive target  cells. Second, we present 
further  arguments  for  the  absence  of allogeneic restriction  in  this  system.  Finally, 
evidence  suggesting  an  HLA-linked gene  control  of the  development  of anti-EBV 
CTL is presented, most individuals exhibiting a  strong CTL response being HLA-A1 
positive. 
Materials  and  Methods 
Effector Lymphocytes.  Blood samples were collected at the acute phase of the disease from 25 
patients  with  infectious mononucleosis assessed  by  a  positive PauI-Bunnel-Davidsohn  test. 
Peripheral blood lymphocytes (PBL)  were  purified by centrifugal sedimentation on  Ficoll- 
Hypaque gradients (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.). To 
avoid any spontaneous nonspecific cytolysis of the lymphoblastoid cells used as targets, further 
purification of T  cells was required. This was achieved by removal of Fc ),-receptor-positive 
lymphocytes  including  most  natural  killer  (NK)  cells  in  man  (12,  13).  EA  rosettes  were 
performed according to a  previously published method  (14)• EA rosette-forming cells (RFC) 
were  removed  by centrifugation on  FicolI-Hypaque gradients.  For complete abrogation of 
nonspecific killing, it appeared necessary to repeat this procedure twice. In some cases, effector 
lymphocytes were frozen in 5% dimethylsulfoxyde (DMSO) and stored in liquid nitrogen. 
Target Cells.  Various EBV-positive and -negative lymphoblastoid cell lines were maintained 
in our laboratory in  RPMI  (Gibco, Glascow, U.  K.)  medium supplemented with  10%  heat- 
inactivated fetal calf serum. In our assays, cells from the following EBV-positive lines were used 
as targets: Daudi-lacking HLA-A, B, and C  products (15) and Raji (HLA A3, A10, B18, and 
B35), both originating from human Burkitt's lymphomas; T5-1  (HLA AI, A2, B8, B27, DR1, 
and  DR3)  and  HLA-homozygous cell  lines  (provided by  W.  F.  Bodmer,  Oxford,  U.  K.) 
established by  the  in  vitro EBV-transformation  of B  cells from  healthy donors.  The  latter 
included PGF (HLA A3-B7), Priess (HLA A2-B15), and Madura  (HLA A2-B9). T5-1  MHC 
variants (16) served as target cells in some experiments. These included variants 4.22•8,  10.9.6, 
7.2.8,  and  6.1.6.  lacking expression of HLA-A2, A2 and  B8,  A1,  DR1,  and  DR3  antigens, 
respectively. Finally, EBV-negative HLA antigen lacking K-562 cells served as reference targets 
for natural killing because of its remarkable sensitivity to NK cell cytotoxicity (17). 
HLA Phenotyping.  Effector cell HLA phenotypes were determined by the classical microlym- 
phocytotoxicity assay (18). 
Cytotoxicity Assay.  Target cells (3 ×  106 in 0.2 ml medium) were labeled by incubation with 
•  51  0.1 ml (100/~C 0 of  Cr as sodmm chromate (New England Nuclear, Boston, Mass.) for 45 min 
at 37°C, washed twice in 50 ml Hanks' solution (Institut Pasteur, Paris), and resuspended at 
105 cells/ml. 0.1 ml of this suspension was then mixed with 5 ×  105 fresh or thawed purified T 
lymphocytes in a final vol of 0.2 ml at a 50:1  effector cell to target cell ratio, in flat-bottomed 
Cook microtiter plates (Greiner, Nfirtingen, West Germany). After a 4-h incubation at 37°C in 
a  5% CO2 humidified incubator, 0.1  ml of the supernates were harvested for counting of the 
radioactivity released  in  a  gamma-counter  (Intertechnique,  Paris,  France).  A  spontaneous 
release control and a maximum release control were included in all assays and consisted of 0.1 
ml medium or HCI 6 N, respectively, added in place of effector lymphocytes. Mean counts in 
triplicate tests were determined. Percent specific lysis (SL) were calculated as: 
E-S 
%SL-  --×  100; 
M-S 
where  E,  S,  and  M  represent  mean  experimental,  spontaneous,  and  maximum  releases, 1312  HLA-LINKED  CONTROL  OF  ANTIVIRAL  CYTOTOXIC  T  CELLS 
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Fig.  1.  Effect  of one  and  two  EA-IgG  rosette-forming cell  depletion  cycles  on  cell-mediated 
cytotoxicity by PBL from IM patients to various target cells: T5-1  (EBV-positive, HLA-positive), 
Daudi  (EBV-positive,  HLA-negative),  K-562  (EBV-negative,  HLA-negative,  NK  cell  sensitive). 
The cytotoxic activity was measured in a 4-h nlchromium release assay at a  50:1 effector:target cell 
ratio. Values are the means of three replicate wells. SE are <5% in all cases. 
respectively.  The spontaneous release  usually ranged from  12 to  18% of the maximum 5]Cr 
released  in the HCI controls. 
Cytotoxicity Inhibition Experiments.  Cytotoxicity inhibition  experiments were  performed by 
adding various antibodies to the assay medium: rabbit anti-human f12 microglobulin antiserum; 
F(ab)'2  fragments of polyspecific  human IgG anti-HLA-A, B, and C antibodies; monoclonal 
anti-fl2 microglobulin (BBM.1)  (19); and anti-HLA 0N6/32)  antibodies, the latter reacting 
with all HLA-A, B, and C molecules  (20), both provided by W. F. Bodmer (Oxford, U. K.); 
and finally, a polyspecific human anti-HLA-DR serum was used as control. 
Results 
Involvement of HLA  Molecules in Antiviral  T-Cell-mediated Lysis.  When  investigating 
T-cell-mediated cytotoxicity in  man,  especially when  lymphoblastoid cell  lines  are 
used as targets,  great care has to be taken  to avoid spontaneous  lysis by NK cells. 
Because human NK cells  (12-13),  as well as B  cells, have been shown  to carry Fcy 
receptors,  PBL  from  IM  patients  were  depleted  of EA-IgG RFC.  The experiment 
shown in Fig.  1 illustrates the effect of one or two depletion cycles of EA-IgG RFC on 
lymphocyte-mediated cytolysis towards  T5-1,  Daudi,  and  K-562  cells.  Unfraction- 
hated PBL were able to kill all three targets. One cycle of EA-IgG RFC removal left 
a lymphocyte population still containing 6% RFC. This effector population exhibited 
a slightly decreased cytotoxicity on T5-1 target cells and a reduced, but still significant, 
killing of Daudi and K-562 cells. After retreatment using the same procedure, no EA- 
IgG RFC could be found in the purified population which no longer killed Daudi or 
K-562 target cells while still exerting consistent cytotoxicity towards T5-1 cells. This 
two-step  purification  is  therefore  necessary  to  abrogate  fully  NK  cell  activity  as M.  LIPINSKI ET  AL. 
TAaLE  I 
Inhibition of the T-Cell-mediated Lympholysis of T5-1  Target Cells by Various Antibodies 
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Antibodies* 
Exp 1  Exp 2  Exp 3  Exp 4 
SL:I:  Inh§  SL  Inh  SL  Inh  SL  Inh 
0  15.7  29.6  35.0  12.0 
Anti-fl2 microglobulin  1.4  91.1  24.6  29.7  6.6  45.0 
F(ab)'2 anti-HLA  8.3  72.0  24.7  29.4  7.8  35.0 
Anti-HLA-DR  17.0  0  27.8  6.1  36.6  0  18.0  0 
0  14.71[  6.411 
Antibodies 
Exp 5 
SL  Inh 
22.9 
Anti-fl2 microglobulin  -0.5  100 
Monoclonal  anti-fl2  micro-  7.5  67.2 
globulin 
Monoclonal anti-HLA  14.2  38.0 
* Conventional  (Exp 1-5) and monoelonal (Exp 5) antibodies described in Materials and Methods were 
added to the incubation  medium during the 4-h 5~Cr release assay. Effector to target cell ratio was 50:1. 
Values are the means of three replicate wells. SE are <5% in all cases. 
:~ Percent specific lysis. 
§ Percent inhibition of specific lysis. 
H  Effector cells preincubated with anti-fl2 microglobulin serum. 
assessed by the final absence of killing of the EBV-negative, NK cell-sensitive K-562 
target.  Moreover,  the  purified  subpopulation  was  unable  of mediating  antibody- 
dependent cell-mediated cytotoxicity (ADCC), as assessed by the absence of lysis of 
L 1210 cells in the presence of rabbit anti-L 1210 cell antiserum (data not shown). This 
rules  out  the  involvement  of anti-EBV  ADCC  in  the  measured  anti-EBV  killing 
mediated by lymphocytes from patients with high titers of anti-EBV antibodies. This 
purification procedure results in T-effector cells cytotoxic towards the EBV-positive, 
HLA-positive  T5-1  target  cells  but  noncytotoxic  to  EBV-positive,  HLA-negative 
Daudi cells. We have used this procedure in all these studies. 
To further analyze the involvement of HLA molecules in the target structure(s) for 
antiviral CTL,  we have  attempted to inhibit T-cell-mediated cytolysis of the EBV- 
genome carrying T5-1  cells with  various anti-fl2 microglobulin and  anti-HLA anti- 
bodies. Table I  shows  that  the addition to the assay medium  of rabbit anti-human 
f12  microglobulin and  of F(ab)'2  fragments  of polyspecific human  anti-HLA-A, B, 
and C  antibodies consistently inhibited T5-1  cytolysis by T  cells from  patients with 
IM. In contrast, addition of human polyspecific anti-HLA-DR antibodies was without 
effect.  The  use of monoclonal  antibodies anti-fl2 microglobulin  (BBM-1)  and  anti- 
HLA  (W6/32)  reacting with  all the HLA-A, B, and  C  molecules also inhibited the 
reaction confirming the previous data  (Table I). The observed inhibitory effect was 
not a  result of interaction of the antibodies with the effector cells because preincuba- 
tion  of the  latter with  anti-fl2  microglobulin  serum  did  not  affect  their  cytotoxic 
activity (Table I). 1314  HLA-LINKED CONTROL  OF ANTIVIRAL CYTOTOXIC  T  CELLS 
TABLE II 
Cytotoxicity to T5-l-variant Target Cells. Effect of Differential HLA Antigen Expression 
Target cell  Progenitor type  Variants 
Exp  1 
T5-1  4.22.8  10.9.6 
HLA antigen expression  A 1  A2  A 1  --  A 1  -- 
B8  B27  B8  B27  --  B27 
DR1  DR3  DRI  DR3  DR1  DR3 
Specific lysis*  44.2 + 4.9  43.5 _  2.0  45.1 _+ 5.3 
Exp 2 
T5-1  7.2.8  6.1.6 
HLA antigen expression  A1  A2  --  A2  A1  A2 
B8  B27  B8  B27  B8  B27 
DR1  DR3  DR1  DR3 
Specific lysis  15.1 + 4.5  14.3 + 3.1  20.2 +_ 4.8 
* Values are means  +  SE of triplicates. 
The presence of accessible HLA  molecules on  the T5-1  target cell surface having 
thus  been  shown  to  be  necessary  for  anti-EBV  T-cell  killing, we  have  studied  the 
respective role of the HLA-A, B, and D  determinants, using as targets T5-1  variants 
which have selectively lost one or two HLA antigens. Table II shows that neither loss 
of HLA-A2, HLA-A2 and B8, HLA-A1, nor HLA-DR  1 and 3 determinants impaired 
the antiviral cytolysis, suggesting no preferential involvement of any of these antigens 
with the target structure(s)  recognized by anti-EBV CTL. 
HLA-linked Control of the Development of Anti-EBV CTL.  In a series of 25 IM patients 
studied, it appeared that T  lymphocytes from only 9  individuals were able to exert 
significant cytotoxicity towards  T5-1  target  cells. The  data are  given  in  Table  III. 
Strikingly, seven  of these  nine  patients  with  detectable anti-EBV  CTL  shared  the 
HLA-A 1 antigen, whereas none of the patients lacking detectable CTL were HLA-A 1 
positive. This observation does not reflect an increase in HLA-Al-positive individuals 
among IM patients, because the distribution of HLA antigens in this group as well as 
in groups studied by other authors  (21)  does not significantly differ from that of the 
healthy control population. Furthermore, among the patients without detectable anti- 
EBV CTL,  the distribution was similar to that  found in a  control population for all 
HLA antigens, except for the total absence of HLA-A 1. The mean specific lysis of T5- 
1 target cells by CTL from HLA-Al-positive patients was 29.7  vs. 0.6%  in the HLA- 
Al-negative  group  (Fig.  2).  This  difference  is  highly  significant  according  to  the 
Student's t test (t -- 7.8, P  <  10-9). 
Lack of Allogeneic Restriction in Anti-EBV T-Cell-mediated Cytolysis.  We have reported 
previously (10)  and in the present work that  the expression of HLA molecules at the 
target cell surface was necessary for lysis by anti-EBV CTL. The question obviously 
arises as to whether this killing is HLA-restricted. It can be seen from Table III that 
among  patients  developing detectable CTL  towards  T5-1  target  cells,  the  level of 
cytotoxicity is not  correlated with  the number  of HLA  specificities shared  between 
effector and  target  cells. For example, CTL  from  patient  1 sharing only one  HLA 
specificity with T5-1, exerted a  specific lysis of 44.2%,  whereas CTL  from  patient  2, 
sharing two HLA specificities with the target cells exerted 42.2% of specific lysis at the 
same effector:target cell ratio. CTL  from patient 8,  without  any HLA specificity in 
common  with  Y5-1  cells nevertheless exerted a  significant cytotoxicity towards  this M.  LIPINSKI  ET  AL. 
TABLE  III 
Cytolysis of EBV-posit,ve  T5-1  Target Cells by Peripheral T Cells  from 25 
IM Patients 
Effector cell 
HLA phenotype  T5-1  target cell* 
Patients  specific lysis 
A locus  B locus 
1  1,  11  12, 21  44.2 -t- 4.9 
2  1, 31  _8,  42.2 ±  2.9 
3  ~, 25  8, 22  35.0 ±  1.8 
4  ~, 33  8, 17  29.6 ±  1.9 
5  _~, 29  -7, 12  22.9 ± 0.5 
6  1, 32  8,  14  22.4 +  1.5 
7  2, 31  8,  12  16.4 +  1.0 
8  25, 31  1-2, 15  15.1:1:4.5 
9  1, 26  8,  12  12.0 ±  1.7 
10  7, 31  8, 40  3.7 + 0.9 
11  "3, 11  8,40  3.5+  1.0 
12  28, 32  5,  18  3.2 ±  0.7 
13  29,-  12, --  2.2 + 0.9 
14  2,  11  5,  8  1.0±0.8 
15  2~, 31  27, 33  -0.3 ±  0.9 
16  2,-  12, 38  --0.6 +  1.9 
17  2,  11  12,--  --1.8 ±  1.7 
18  "2,  9  12, 27  --2.4 +  1.3 
19  25, 25  12, 2"-i  --1.8 ±  0.2 
20  3, 28  7, 40  --2.0 ±  1.1 
21  3,  11  5,  14  --3.5±0.5 
22  2,  9  5, 27  --4.3 ±  0.3 
23  2,-  7,  12  --4.9 ±  1.0 
24  -3, 31  21, 27  --4.8 ±  0.7 
25  2,  3  15, 39  --7.l -1- 0.5 
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The T-cell-mediated cytotoxicity assay is performed as described in Materials 
and  Methods. Specific  lysis values  are mean percent specific lysis +  SE of 
triplicates.  Effector cell HLA antigens are underlined when present  in the 
T5-1  HLA phenotype. 
* T5-1 HLA phenotype: A1, A2, BS, B27. 
target  (15.1%)  as compared,  for example,  to the cytotoxicity exhibited by CTL  from 
patients  7  (16.4%)  and  9  (12%)  sharing two HLA  specificities with T5-1  cells. On  the 
other hand,  among  the  patients  who  did  not  develop detectable  CTL  towards  T5-1 
target  cells,  it  is  noteworthy  that  4  of  16  shared  two  specificities and  7  shared  one 
specificity with the target  cells (Table III). 
Tables  IV  and  V  report  experiments  in  which  T  lymphocytes  from  different  IM 
patients  were  tested  against  various  EBV-positive  target  cells.  The  CTL  from  five 
patients  which  exerted  significant  cytotoxicity  towards  T5-1  target  cells  were  also 
cytolytic towards  the other target cells tested  (Raji and  PGF) regardless of their HLA 
compatibility  (Table  IV).  In  7  of  12  cytotoxic  combinations,  there  was  no  HLA 
specificity in common  between effector and target cells, indicating that  HLA  antigens 
do not act  as restriction elements in this system. 
The  lack  of detectable  CTL  towards  T5-1  target  cells  in  some  patients  left  the 
possibility that cytotoxicity could be found in fully compatible HLA-A  and B effector- 1316  HLA-LINKED CONTROL  OF  ANTIVIRAL CYTOTOXIC  T  CELLS 
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Fie.  2.  Cytolysis of T5-1  target  cells  by peripheral blood T  lymphocytes HLA-AI  positive and 
negative IM patients. Reactions were performed as described in Materials and Methods. Each bar 
represents the average specific  lysis for each group. 
TABLE  IV 
Lack of Allogeneic Restriction in IM Patient  T-Cell-mediated  Cytotoxicity against EB V- 
positive  Target Cells 
Effector cells  Target cells* 
Patient  HLA phenotype  T5-1  Raji  PGF 
7  A2A31B  8B12  16.4+1.0  11.6+0.8  17.7  +  1.2 
6  A1 A32 B  8 BI4  22.4 +  1.5  12.7  ±  1.I  16.0  +  1.8 
2  AI A31 B  8  42.2  ±  2.9  22.1  ±  1.4  12.5  ±  1.0 
1  A1 All B12 B21  44.2  +  4.9  62.1  +  4.2 
5  A1  A29B  7B12  22.9±0.5  23.0+0.7 
Values represent mean percent specific  lysis +  SE of triplicates. 
Values are underlined where no HLA-A or B antigen is shared between effector and target 
cells. 
* Target cell  HLA phenotypes: T5-1, AI, A2,  B8,  B27;  Raji:  A3,  AI0, B18,  B35;  PGF A3, 
B7. M.  LIPINSKI ET AL.  1317 
TAnLE V 
Lack of Killing of HLA-homozygous EBV-positive Lymphoblastoid Target Cells by T Cells  from HLA- 
compatible IM Patients 
Effector cells  Target cells 
Patient  HLA phenotype  T5-1 
HLA-homozygous lines* 
Priess  ARNT  Madura 
25  A2A3  B15B39  -7.1+0.5  -0.4+  1.1  -2.5±0.7 
10  A2A31B40B8  3.7 +0.9  -11.1  ±  1.7 
* HLA-homozygous line phenotypes: Priess, A2, B15; ARNT, A2, B39; Madura A2, B40. Values represent 
mean percent specific lysis +  SE of triplicates. 
target cell combinations. This does not appear to be the case, because T  lymphocytes 
from patient 25 are not cytotoxic towards the EBV-positive, HLA-A and B homozy- 
gous Priess and ARNT cells, which  are HLA-A and B compatible with the effector 
cells (Table V). Similar data were obtained using lymphocytes from patient  10 which 
did not kill the EBV-positive, HLA-A and B homozygous Madura target cells in spite 
of its HLA-A and B compatibility with the effector cells (Table V). 
Discussion 
The present study concerns the role of the human MHC in the cytotoxic response 
of T  cells from patients with IM towards EBV genome-containing target cells. First, 
we investigated the role of HLA products at" the target cell surface and second,  the 
possible involvement of MHC  genes in the control of the cytotoxic T-cell response. 
The data herein presented show that, after complete elimination of NK and K  cells 
has been achieved, T  cells from patients with IM are cytotoxic towards EBV-positive 
cells only if HLA-A, B  and C  molecules are expressed on the target cell membrane. 
After one cycle of EA-IgG RFC removal, Daudi cells could be occasionally killed. In 
such  cases,  the  purified  lymphocyte  population  was  still  able  to  mediate  ADCC 
against  L1210 cells in the presence of ant i-Ll210 antiserum.  We therefore conclude 
that the observed lysis of Daudi cells could be related to both remaining spontaneous 
cytotoxicity and  ADCC  through  anti-EBV  antibodies.  Furthermore,  the  fact  that 
anti-EBV  T  cell  lysis  is  consistently  inhibited  by anti-fl2  microglobulin  and  anti- 
HLA-A, B,  and  C  antibodies,  argues  further for the  role of HLA molecules at  the 
target cell surface in this system. This inhibition is not a result of interaction with the 
effector cells, because preincubation of the latter with anti-fl2 microglobulin antibod- 
ies  is  without  effect. The recognition  of HLA-D products  by T-effector cells  is  not 
necessary for anti-EBV  killing because anti-HLA-DR antibodies  did  not  affect the 
cytotoxic reaction. That Daudi cells, though carrying the HLA-DR6 antigen (22)  are 
indeed  resistant  to  anti-EBV  T-cell-mediated  cytotoxicity,  further  indicates  that 
HLA-D products cannot act as recognition structures in this system. Moreover, T5-1 
6.1.6  variant cells which  do not  express  HLA-D products were as sensitive to anti- 
EBV CTL as the wild type T5-1 cells. 
In this system, despite the fact that the expression of HLA products is necessary for 
anti-viral T-cell-mediated killing, we did not find any evidence for allogeneic restric- 
tion.  The  lack of restriction  was established  by the  following arguments:  (a)  CTL 1318  HLA-LINKED CONTROL  OF ANTIVIRAL CYTOTOXIC  T  CELLS 
from one given individual  could  exert  a  similar magnitude  of cytotoxicity towards 
different EBV-positive cells, regardless of the number of HLA antigens shared by the 
effector and  target  cells,  (b)  in  several cytotoxic combinations,  CTL from patients 
with IM were able to kill target cells with which they shared no HLA specificity, (c) 
finally, variant T5-1 cells, lacking one or two HLA antigens at the A and B loci, were 
killed to the same extent as the wild-type cell line, indicating the lack of preferential 
involvement of any  antigen  in  the  target  structure(s)  recognized  by the  anti-EBV 
CTL. Cytolysis of EBV-positive allogeneic target cells is indeed EBV-specific and is 
not  a  result  of alloreactive  CTL  generated  during  the  response  to  EBV  infection 
because  it  is  well  substantiated  that  T  cells  from  patients  with  IM  cannot  kill 
allogeneic EBV-negative cells (9,  10). Thus, this situation is clearly different from the 
murine TNP model in which allo-reactive CTL can cross-react with TNP-modified 
syngeneic target cells (23). 
The lack of allogeneic restriction observed in our data has, however, to be tempered 
by the fact that EBV-infected cells expressed as much as 36 times more HLA molecules 
at  their  surface  than  normal  lymphocytes  (24).  This  could  reveal  cross-reactivity 
between allo-antigens that are not detectable using conventional target cells. Further- 
more, it remains possible that virus-infected cells, especially when transformed, express 
extra MHC  specificities (25)  which  may mimic the self antigens of effector T  cells. 
However,  it  is  striking  that  in  no  case  were  CTL  from  one  patient  able  to  show 
preference for one given EBV-positive cell line.  This favors, therefore, the idea that 
there is a real absence of allogeneic restriction in this system. These results appear to 
conflict with results from several murine (26-29) and human (1-3) systems. However, 
unrestricted models such as the CTL response to Senda'i-infected murine target cells 
(5)  and  to TNP-modified cells  (6)  have been  described.  The response of human T 
cells to TNP-modified targets, though species restricted, is not HLA restricted which 
argues in  favor of the hypothesis that  CTL recognize TNP in conjunction  with an 
antigen widely shared among humans but absent from mice (4). Similarly, the in vivo 
generated T  cells may recognize EBV-coded antigens in association with a public or 
constant  part  determinant  born  by  the  HLA-A,  B,  and  C  products  or  with  /~2 
microglobulin. 
The  MHC,  besides  coding  for molecules  involved  in  target  structures  for CTL, 
contains genes governing the magnitude of immune responses. MHC-linked Ir as well 
as immune suppression  (Is) genes controlling antibody production have been clearly 
demonstrated (30).  It has been shown recently in the mouse that genes located in the 
H-2I region  govern  the capacity of CTL to recognize either  H-2K or H-2D TNP- 
modified target cells (31). Similar data have been obtained in studies of the response 
to  H-Y  (32)  or  murine  sarcoma  virus-coded  (33)  antigens.  In  man,  in  the  HLA- 
restricted  T-cell  killing  of influenza  virus-infected  target  ceils  (1),  it  is  striking  to 
observe that most individuals carrying the HLA-A2 antigen do not develop anti-viral 
CTL  in  vitro  (34).  This  result  can  be  interpreted  in  terms  of an  HLA-A2-1inked 
gene(s)  governing unresponsiveness to influenza-coded  antigens.  In a  similar model, 
Shaw and Biddison have recently shown that, within a  large family, HLA identical 
siblings exhibit  identical  patterns of anti-influenza  T-cell-mediated cytolysis against 
different target cells (35). 
In the system studied  here, using CTL against  EBV-coded antigens developed in 
vivo during the course of IM, we have shown that T  lymphocytes from only 9 of 25 M.  LIPINSKI  ET  AL.  1319 
patients were cytotoxic against EBV-positive target cells. 7 of these 9 patients carried 
the HLA-A1 antigen, whereas none of the  16 patients lacking detectable CTL were 
HLA-A1  positive. These data favor the hypothesis of an  HLA-Al-linked gene con- 
trolling development of anti-EBV CTL. The mean specific lysis of T5-1  target cells 
by  CTL  from  HLA-Al-positive  patients  was  29.3  vs.  0.6%  for  HLA-Al-negative 
patients (P <  10-9). The distribution of HLA-Al-positive individuals within the two 
groups of patients is strikingly different from the frequency of HLA-A1 in a control 
population (23.4%). This unusual distribution does not reflect any selection of HLA- 
Al-positive individuals among IM patients because in our group (%s =  28%)  as well 
as in reported studies  (21), there is no abnormal  frequency of the HLA-A1  antigen 
nor of any other HLA-A or B antigen tested. However, some features of the course of 
the disease peculiar to HLA-A1 positive patients cannot be excluded. Larger clinical 
studies are needed to clarify this point. 
That the magnitude of the anti-EBV response in IM patients is controlled by an 
HLA-linked gene(s) can be tentatively explained in several ways: (a) HLA-Al-linked 
gene(s) govern some nonimmunological parameters concerning EBV infection such as 
the level of viremia or the kinetics of virus clearance in the organism (8).  Similar H- 
2-1inked genes have been actually described in the control of Moloney viremia (36). 
(b)  Ir gene(s) control the development of CTL. HLA-Al-linked gene(s)  may govern 
either the proliferative response of T  cells towards EBV-infected cells, or the differ- 
entiation of precursors to mature CTL, or both phenomena. A possible explanation 
of our observation is that T  cell from HLA-Al-negative IM patients do proliferate in 
response to the virus but do not undergo differentiation to mature CTL to the same 
extent as T  cells from HLA-Al-positive patients. Interestingly, T  cells from HLA-A2 
individuals which frequently do not generate anti-influenza virus CTL (34), never- 
theless exhibit a  normal proliferative response in the presence of influenza infected 
cells  (A. J.  McMichael.  Personal communication.). The existence of Ir genes is well 
documented  (30).  A  new  type  of Ir  gene(s)  controlling  the  expression  of MHC- 
unrestricted CTL to hapten-modified target cells has been described recently (37). In 
view of these data, the hypothesis that  HLA-Al-positive IM patients develop unre- 
stricted CTL, whereas T  cells from HLA-Al-negative patients  are subject  to strict 
allogeneic restriction is worth considering. This does not however appear to be the 
case because T  cells from those patients which are not cytotoxic towards EBV-positive 
allogeneic target cells are equally unable  to kill  fully HLA-matched  EBV-positive 
cells.  (c)  An  Is  gene present  in  all  individuals  but  the  HLA-Al-positive subjects  is 
responsible for the absence of CTL observed in HLA-Al-negative patients. 
It  is noteworthy that  the HLA-Al-linked Ir  (or Is)  gene postulated  in  this work 
would  be located close to the HLA-A locus, whereas the HLA-D region has so far 
been considered to be the human equivalent of the murine H-2I region. 
Summary 
Peripheral  T  lymphocytes from patients  with  infectious mononucleosis  (IM)  are 
sensitized in vivo against the Epstein-Barr virus (EBV). The expression of HLA-A, B, 
or C molecules at the target cell surface is necessary for the cytotoxic reaction because 
(a) EBV-positive Daudi cells lacking HLA-A, B, and C  determinants are resistant to 
anti-EBV T-cell lysis,  (b)  cytolysis of EBV-positive target  cells can  be consistently 
inhibited by anti-HLA-A, B, and C and anti-fl2 microglobulin antibodies. However, 1320  HLA-LINKED  CONTROL OF ANTIVIRAL CYTOTOXIC T  CELLS 
no evidence for allogeneic restriction  in this system was apparent  as  (a)  cytotoxic T 
lymphocytes (CTL) from one given individual could exert a  cytotoxicity of a  similar 
magnitude on different EBV-positive target cells, regardless of the number of HLA-A 
or B specificities shared by the effectors and targets;  (b) CTL from IM patients were 
able  to kill  target  cells without  any HLA-A or B  antigen  in common; and  (c)  T5-1 
variants  lacking one or two HLA antigens  at  the A, B, or D  locus are  killed  to the 
same extent  as the parental  cells.  7 of the 9  IM patients  with  detectable  circulating 
anti-EBV  CTL  carried  the  HLA-A1  antigen,  whereas  none  of the  16  IM  patients 
lacking detectable peripheral  CTL were HLA-A1 positive  (mean specific lysis of T5- 
1 target  cells  by T  cells  from HLA-Al-positive patients:  29.3  vs. 0.6%  in  HLA-A1- 
negative patients)  (P <  10-9). These data suggest an HLA-Al-linked gene control of 
the magnitude of the anti-EBV CTL response. Thus, the HLA region appears to act 
at two different levels in the T-cell-mediated lysis of EBV-infected cells by controlling 
first, the development  of anti-EBV and second,  the expression  of HLA-A, B, and C 
molecules involved as recognition structures at the target cell surface. 
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